Stock Price Quote

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE1580.55-26.25 (-1.63 %)
PREV CLOSE ( ) 1606.80
OPEN PRICE ( ) 1607.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1580.00 (1)
VOLUME 15690
TODAY'S LOW / HIGH ( )1576.85 1614.60
52 WK LOW / HIGH ( )680.35 1703.8
NSE1580.05-23.6 (-1.47 %)
PREV CLOSE( ) 1603.65
OPEN PRICE ( ) 1602.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1580.05 (336)
VOLUME 849166
TODAY'S LOW / HIGH( ) 1577.45 1614.00
52 WK LOW / HIGH ( )680 1704.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1983
Management Info
Manju D Gupta - Chairman Nilesh Gupta - Managing Director
Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

22Apr Lupin launches Mirabegron Extended-Rel
Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the Un..
22Apr Lupin jumps on launching Mirabegron Ex
Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% f..
22Apr Lupin informs about board meeting
Pursuant to Regulation 29(1)(a) of SEBI (Listing Obligation and Disclosu..
18Apr Announcement under Regulation 30 (LOD
Intimation regarding allotment of 59809 shares under ESOP.
15Apr Lupin informs about stop transfer
Lupin has informed that it enclosed the details of share certificate, re..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit9164.399999999994252.10000000001
Gross Profit 10839.6 5271.40000000001
Operating Profit 1240511739.2
Net Sales 41157.5112588.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)390.76
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95896.87
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89224.37
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26893.07
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91

Shareholding Pattern

NON-INSTITUTION 6.93%
PROMOTERS 47.01%
MUTUAL FUNDS/UTI 16.82%
FI/BANKS/INSURANCE 10.02%
GOVERNMENT 0.01%
FII 0%

About Lupin Ltd.

Lupin Ltd. was incorporated in the year 1983. Its today's share price is 1580.55. Its current market capitalisation stands at Rs 72033.58 Cr. In the latest quarter, company has reported Gross Sales of Rs. 113193.3 Cr and Total Income of Rs.114688.5 Cr. The company's management includes R V Satam, Mark D McDade, Punita Kumar Sinha, K B S Anand, Jean-Luc Belingard, Ramesh Swaminathan, Nilesh Gupta, Vinita Gupta, Manju D Gupta.

It is listed on the BSE with a BSE Code of 500257 , NSE with an NSE Symbol of LUPIN and ISIN of INE326A01037. It's Registered office is at Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East)Mumbai-400055, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arora & Arora, BSR & Co LLP, Deloitte Haskins & Sells, Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SS Kapoor & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.